‘Incredibly frustrating': YVR laments weekend of extensive delays
Vancouver International Airport is expecting its busiest summer ever, and it's off to a rough start, following a weekend with major flight delays due to a shortage of air traffic controllers.
There were more than two hundred flight delays over the weekend and dozens of cancellations, when crowds were travelling ahead of Canada Day.
'Saturday (was) an incredibly frustrating day for passengers,' Stephen Smart, the airport's head of communications told CTV News on Monday. 'Incredibly frustrating day for our partners. Incredibly frustrating day for us.'
The airport has pointed to what it calls resource restraints with air traffic controllers as the reason for the disruption.
Some were unavailable to work with little-to-no notice during one of the airport's busiest weekends, according to Smart.
'NAV Canada had that last minute staffing issue come up, and as a result they had to dial back how many aircraft they could handle coming into YVR at any given hour,' Smart said.
The frustration is also being felt by airlines.
'Canadians deserve consistent accountability and service standards across the entire aviation eco-system,' a statement from WestJet said adding that the airline is 'calling on the federal government to work with all stakeholders to find an immediate solution to support the structural challenges that NAV Canada is facing.'
Air Canada also shared its concerns.
'The issue seriously affects passengers not only flying to/from YVR, but across Air Canada's network, as knock-on effects from aircraft and crews which are delayed in YVR can then be delayed at other airports downline,' a statement from the airline said.
'We are engaged in dialogue with NAV Canada and expect solutions that will allow the country's air transport ecosystem to operate smoothly and meet Canadians' and global passengers' travel expectations going forward.'
NAV Canada said it is dealing with staff shortages and regrets the impact delays is having on travellers.
'Our team is doing everything it can to ensure aircraft are moving, first and foremost safely, but also efficiently and we regret any impacts to the flying public,' said Jonathan Bagg with NAV Canada.
By Monday, operations were mostly back to normal, in time for what the airport anticipated would be the busiest day of a quasi-long weekend.
But with a busy travel season ahead – some have concerns further turbulence could be ahead.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
20 minutes ago
- CBC
Canada's Gilgeous-Alexander agrees to massive 4-year extension with NBA champion Thunder: reports
Social Sharing Shai Gilgeous-Alexander and the Oklahoma City Thunder have agreed on a record-setting 4-year, $285 million US extension that would give him the highest single-season average salary in NBA history, a person with knowledge of the agreement said Tuesday. The person spoke to The Associated Press on condition of anonymity because the deal has not been publicly announced and likely won't be until the league's moratorium on most offseason signings is lifted on Sunday. ESPN first reported on the agreement. News of the deal comes on Canada Day, a fitting coincidence for the 26-year-old from Hamilton who is coming off a season like few others in NBA history. Not only did Gilgeous-Alexander lead the Thunder to their first NBA championship and the league's best record, he swept most major individual awards — winning regular-season and NBA Finals MVP honors and the scoring title. The supermax extension was not unexpected. It was a question of timing; he could have taken a deal with an even higher total value next summer. Based on the NBA's most recent salary cap projections — the exact numbers will not be finalized until June 2027 — Gilgeous-Alexander would make somewhere around $63 million in the first season and nearly $79 million during the 2030-31 season. That would put him at an average payout of about $1 million per regular season game, and would be the highest single-season salary in NBA history. Gilgeous-Alexander didn't enter the league with superstar expectations. He was the 11th overall pick in the 2018 draft, and he was traded from the Los Angeles Clippers to the Thunder after his rookie year. He has been on an upward trajectory ever since, and Thunder general manager Sam Presti believes that will continue. "He's gotten better every single year," Presti said. "His mindset has allowed him to take these steps and also not — I don't feel like his progress is, like, volatile. I don't know if that makes sense, but I don't feel like it's built on things that can't be repeated and built up again." Presti referred to Gilgeous-Alexander as a "basketball artist" because he has the emotional intelligence to know when to call upon his various gifts. "I just think he's got left and right brain working, and I think when you think about people that are extremely successful in what they do, they can't operate all on one side or the other," Presti said. "People have to have — to me, the great people in life, business, sports, any industry, have to be able to access both sides, a creative side and then also a very objective side." The Thunder are set to be contenders for years. Their best player is in place long-term, all their major players are under contract through at least next season and Presti has a slew of draft picks stashed from previous trades.
CTV News
30 minutes ago
- CTV News
Double decker bus back on the street in the Sault
A classic double decker bus in Sault Ste. Marie has been restored and has started ferrying tourists to tourism spots across the city. Cory Nordstrom reports.
National Post
39 minutes ago
- National Post
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
Article content Article content – Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – Article content Article content TORONTO — Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the ' Securities Purchase Agreement ') with High Trail Special Situations LLC (' High Trail '), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the ' Convertible Debentures '). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the ' Private Placement '). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties. Article content 'This financing represents a major inflection point for Cybin and supports our position as a leader within our sector,' said Doug Drysdale, Chief Executive Officer of Cybin. 'High Trail Capital is an experienced investor, and its confidence and appreciation of our breakthrough clinical data and intellectual property portfolio recognize the potential of the Company. This financing comes at an opportune time for Cybin, as we advance our lead programs, CYB003 and CYB004, in Phase 3 and Phase 2, respectively. CYB003 demonstrated over 70% remission rates and continued durability over 12 months for patients with uncontrolled depression. We await the conclusion of our CYB004 Phase 2 proof-of-concept study, in patients with generalized anxiety disorder,' said Drysdale. Article content Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this transaction. Article content Pipeline Acceleration Drives Multiple Value Creation Catalysts Article content The funding will accelerate Cybin's clinical-stage programs across multiple high-value indications: Article content CYB003 Program Achievements: Article content Breakthrough Clinical Results: Unprecedented 71% remission rate in major depressive disorder at 12 months after two 16 mg doses in Phase 2 study Durability advantage: 12-month sustained efficacy demonstrating long-term therapeutic benefit FDA Recognition: Breakthrough Therapy Designation received, expediting regulatory pathway Multinational Phase 3 PARADIGM program underway Article content CYB004 Program Momentum: Article content Dual Indication Strategy: Expanding addressable market opportunity Phase 2 GAD study expected to complete around mid-year 2025 1 Article content Commercialization Infrastructure: Article content Value Catalysts Drive Sustained Momentum Article content Near-Term Catalysts: Article content CYB004 Phase 2 GAD study expected to complete around mid-2025 1 Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025 1 EXTEND study initiation imminent 1 Article content Medium-Term Catalysts (2025-2026): Article content Transaction Terms Article content The Convertible Debentures have a two-year term from the closing date (the ' Term '). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Term. Such interest was pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% per annum on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Trail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%. Article content Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into common shares in the capital of the Company (the ' Common Shares ') at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (' VWAP ') of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion. Article content The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid thereafter, a 3% prepayment premium on the amount of the prepayment. Article content The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. Article content The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. Article content The Convertible Debentures were offered on a private placement basis pursuant to prospectus exemptions in Canada and pursuant to exemptions and exclusions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. The Company has agreed to use commercially reasonable efforts to: (a) file a prospectus supplement to the Company's base shelf prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025, with applicable Canadian securities regulators to qualify the secondary market sales of the Common Shares in the United States; and (b) either (i) prepare and file the Canadian prospectus supplement with the United States Securities and Exchange Commission, or (ii) file a prospectus supplement pursuant to General Instruction II.L of Form F-10 with the United States Securities and Exchange Commission to the Company's registration statement on Form F-10 (File No. 333-284173), which was declared effective by the SEC on January 14, 2025, or on such other form as may be available to the Company, in either case qualifying the resale of the Common Shares underlying the Convertible Debentures. Article content No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, 'forward-looking statements'). Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the use of Private Placement proceeds; the conversion of the Convertible Debentures into Common Shares; the sale and issue of US$450,000,000 principal amount of Convertible Debentures at a future date; CYB004 Phase 2 GAD study expected to complete around mid-2025; Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025; the Company's Medium-Term Catalysts for 2025-2026; Phase 3 PARADIGM program enrollment acceleration; the Company's ability to achieve commercial success; and the Company's ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on and with the SEC on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media Contact Article content : Article content
